Previous 10 | Next 10 |
Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET Biodesix, Inc. (Nasdaq: BDSX), a leading data...
Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Im...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s ...
First data from the ORACLE prospective clinical utility study highlights reduction of invasive procedures on patients with benign nodules Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations w...
Cue Health (NASDAQ:HLTH) has priced its IPO of 12.5M shares of common stock at $16.00/share, for gross proceeds of $200M at a target valuation of around $2.4B. Nasdaq trading commences on September 24, 2021. Underwriters' over-allotment is an additional 1.875M shares. Closing date i...
Data highlight the importance of utilizing genomic and proteomic testing for treatment guidance Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genom...
Today, we take our first look at Biodesix, a small diagnostic firm that just came public last year. The company is experiencing fast revenue growth even as second-quarter results were disappointing. A full investment analysis on Biodesix is provided in the paragraphs below. ...
The following slide deck was published by Biodesix, Inc. in conjunction with this event. For further details see: Biodesix (BDSX) Investor Presentation - Slideshow
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference bein...
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...